Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells

Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells

Adoptive cancer immunotherapy using chimeric antigen receptor (CAR) engineered T-cells holds great promise, although several obstacles hinder the efficient generation of cell products under good manufacturing practice (GMP). Patients are often immune compromised, rendering it challenging to produce...

Full description

Bibliographic Details
Main Authors: May C. I. van Schalkwyk, Sjoukje J. C. van der Stegen, Leticia Bosshard-Carter, Helen Graves, Sophie Papa, Ana C. Parente-Pereira, Farzin Farzaneh, Christopher D. Fisher, Andrew Hope, Antonella Adami, John Maher
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cells
Subjects:
good manufacturing practice
closed process
chimeric antigen receptor
retrovirus
interleukin-4
Online Access:https://www.mdpi.com/2073-4409/10/7/1797

Internet

https://www.mdpi.com/2073-4409/10/7/1797

Similar Items